knowledge -WSS

knowledge

author：knowledge 2025-08-11 16:24:36 - browse：3385

Principal Deputy FDA Commissioner Janet Woodcock Stefani Reynolds/The New York Times via AP

WASHINGTON — Principal Deputy FDA Commissioner Janet Woodcock will retire early next year from the Food and Drug Administration after helping steer the agency through an historic period of medical advances during nearly four decades in key leadership positions, she confirmed to STAT Thursday.

Woodcock, a doctor with a chemistry degree, joined FDA in 1986 at its biologics center, where she oversaw the approval of the first biotechnology-based treatments for multiple sclerosis and cystic fibrosis. In 1994, she was named director of the drug center, where she played a key role in guiding some of the most impactful changes to the regulation of medicine, according to Trump administration FDA Commissioner Scott Gottlieb.

Woodcock envisioned that antibody drugs would become a backbone of therapy and created a more predictable regulatory path for their review and approval, Gottlieb said. She presided over a major expansion and modernization of the generic drug program, standardizing reviews in a way that allowed the industry to become safer and more robust, and crafted the reform of over-the-counter drug reviews.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Maker of FluMist seeks to allow at

WSS

Eli Lilly, Pfizer, and others want in on the online prescription market

Why Sanofi got shellacked over its spinoff

Test for long Covid? Researchers find new clue in blood samples

Chimpanzees, like humans and whales, get menopause: Study

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

eGenesis tests gene

explore

knowledge

focus

After affirmative action ruling, medical educators look to 'holistic review'

Readout Newsletter: New research from Sanofi, Regeneron, etc.

How to save PrEP access — and even expand it

Eli Lilly, Pfizer, and others want in on the online prescription market

Malaria cases in Florida and Texas: Here’s what you need to know

Prior authorization will have to move faster under new Biden rule

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The pink breast cancer awareness ribbon needs a redesign

In age of alternative facts, a scholarly course on calling out crap

Hospitals warn Medicare's drug payment fix is ‘unlawful’

knowledge

Physician subsidies by hospitals soar in wake of No Surprises Act

AI generated plenty of interest at JPM but not a lot of trust

FDA clears AI tool for detecting skin cancer

Readout Newsletter: New research from Sanofi, Regeneron, etc.

Biden's order seeks to regulate AI risk without stifling innovation

Maker of FluMist seeks to allow at

leisure time

focus

focus

hotspot